NEW YORK (GenomeWeb News) — Celera said today it has licensed its estrogen/progesterone receptor patents to LabCorp, which will use the IP to commercialize two cancer tests.
 
The reference lab giant will use one test to predict risk of metastasis in early-stage breast cancer, while the other will assess hormone-receptor status to help plan endocrine therapy.
 
Under the agreement, LabCorp will pay Celera an up-front license fee and royalties on net sales of lab services and tests that use the IP.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.